›› 2019, Vol. 39 ›› Issue (11): 1578-1582.

• 研究论文 • 上一篇    下一篇



  1. 中国石油天然气集团公司中心医院
  • 收稿日期:2018-12-18 修回日期:2019-05-28 出版日期:2019-11-05 发布日期:2019-11-05
  • 通讯作者: 于婧 E-mail:55309190@qq.com

Effect of BRAFV600E mutation on expression of VEGF and MMP-9 in papillary thyroid carcinoma

  • Received:2018-12-18 Revised:2019-05-28 Online:2019-11-05 Published:2019-11-05
  • Contact: Jing YU E-mail:55309190@qq.com

摘要: 目的 探讨甲状腺乳头状癌(PTC)BRAFV600E基因突变与多种分子标志物表达及肿瘤临床病理特征的关系。探讨该突变是否为预后不良指标。方法 用实时荧光定量PCR检测标本BRAFV600E mRNA,用免疫组化PV法检测标本galectin-3、cyclin D1、VEGF和MMP-9蛋白表达。结果 104例PTC中的71例(68.3%)BRAFV600E基因突变(+),突变组的肿瘤直径增大、肿瘤T分期较高、更易侵犯甲状腺被膜外及淋巴结转移,且VEGF、MMP-9蛋白表达阳性率升高(P<0.05)。二元Logist回归分析显示BRAFV600E基因突变(+)的PTC VEGF蛋白高表达,肿瘤直径增大、更易侵犯甲状腺被膜外组织且肿瘤T分期较高(P<0.05)。结论 BRAFV600E基因突变的PTC具有更高的侵袭性和转移潜能。

关键词: 甲状腺乳头状癌,BRAFV600E基因突变,血管内皮生长因子,基质金属蛋白酶9

Abstract: Objective To investigate the relationship between BRAFV600E mutation in PTC and the expression of various molecular markers and the clinicopathological characteristics of the tumor. Predict that BRAFV600E mutation is an indicator of poor prognosis. Methods The BRAFV600E mutation was detected by real-time PCR, and the expressions of galectin-3, cyclin D1, VEGF and MMP-9 were detected by immunohistochemistry. Results Of 104 PTC patients, 71 cases (68.3%) were BRAFV600E mutation (+). These cases had significantly larger sizes, higher tumor T stage, were more likely to invade the thyroid epithelium and lymph node metastasis, and the expression of VEGF and MMP-9 was up-regulated(P<0.05). Binary Logist regression analysis showed that ,the cases with BRAFV600E mutation (+) had significantly higher expression of VEGF protein, larger tumor diameter, and higher T stage of the tumor, more likely to invade the thyroid epithelial tissue(P<0.05). Conclusions PTC with BRAFV600E mutation has a higher invasive and metastatic potential.

Key words: Papillary thyroid carcinoma,BRAFV600E mutation,Vascular endothelial growth factor,Matrix metalloproteinase-9